2022 Revenues ($USD) : $14,367,000,000
2022 R&D spend : n/a
2022 Number of Employees : n/a
Fiscal Year End : 12/31/2021
Company CEO : Robert Ford, CEO; Lisa Earnhardt, EVP medical devices

Abbott kicked off 2022 with CEO Robert Ford delivering the first healthcare keynote ever at CES. Ford used his keynote to reveal that Abbott is developing a new category of biowearables for athletes called “Lingo.” Said Ford: “We’re creating a future that will bring you and your loved ones care that’s more personal and precise. It’s happening right now. And its potential is no less than incredible.” The company has also been on a roll this year with medtech announcements:

• Abbott in January announced FDA approval of new MRI compatibility for the company’s Proclaim spinal cord stimulation system.


• In February, it announced the first implant of its Aveir DR dual-chamber leadless pacemaker system in a clinical trial.


• An FDA expanded indication, also announced in February, means that an additional 1.2 million people in the U.S. with heart failure can take advantage of Abbott’s CardioMEMS HF system. The system remotely monitors pulmonary artery (PA) pressure changes, providing early warning of worsening heart failure.


• In April, the company launched an upgraded version of its NeuroSphere myPath digital health app that enables doctors to more closely track their patients as they trial Abbott neurostimulation devices to address their chronic pain.


• Also in April, Abbott announced FDA approval of its Aveir single-chamber (VR) leadless pacemaker for slow heart rhythms. Abbott’s Aveir is its answer to Medtronic’s Micra leadless pacemakers, which won initial FDA approval in 2016.


• Abbott in May said it had received FDA clearance for its next-generation FreeStyle Libre 3 continuous glucose monitor, designed as the world's smallest and thinnest CGM sensor. –CN